Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4′-hydroxylation status

American Journal of Tropical Medicine and Hygiene

Volumn 54, Issue 2, 1996, Pages 189-196

  Kusaka, Meizo ^a   Setiabudy, Rianto ^a   Chiba, Kan ^a   Ishizaki, Takashi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CHLOROPHENYL)BIGUANIDE; BIGUANIDE DERIVATIVE; CHLOROQUINE; CYCLOGUANIL; DRUG METABOLITE; FANSIDAR; MEFLOQUINE; MEPHENYTOIN; PRODRUG; PROGUANIL; PYRIMETHAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALARIA FALCIPARUM; MALE; MULTIDRUG RESISTANCE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PLASMODIUM FALCIPARUM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TRAVEL;

ADULT; ANTIMALARIALS; BIGUANIDES; CHLOROGUANIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROXYLATION; MALE; MEPHENYTOIN; MIDDLE AGED; PHENOTYPE; TRIAZINES;

PLASMODIUM FALCIPARUM;

EID: 0029864323     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1996.54.189     Document Type: Article

References (45)

1. Moran JS, Bernard KW, 1989. The spread of chloroquine-resistant malaria in Africa. Implication for travelers. JAMA 262: 245-248.
2. Watkins WM, Percy M, Crampton JM, Ward S, Kowch D, Howells RE, 1988. The changing response of Plasmodium falciparum to antimalarial drugs in East Africa. Trans R Soc Trop Med Hyg 82: 21-26.
3. Peters W, 1982. Antimalarial drug resistance: an increasing problem. Br Med Bull 38: 187-192.
4. Spencer HC, 1985. Drug-resistant malaria -changing patterns mean difficult decisions. Trans R Soc Trop Med Hyg 79: 74B-75B.
5. Wyler DJ, 1993. Malaria chemoprophylaxis for the traveler. N Engl J Med 329: 31-37.
6. Brown GV, 1993. Chemoprophylaxis of malaria. Med J Aust 159: 187-196.
7. Bradley D, 1993. Prophylaxis against malaria for travellers from the United Kingdom. Br Med J 306: 1247-1252.
8. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC, 1986. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar®) for malaria prophylaxis. Am J Trop Med Hyg 35: 451-458.
9. Reacher M, Campbell CC, Freeman J, Dobersyn EB, Brandling-Bennett AD, 1981. Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar®). Lancet ii: 1066-1069.
10. Hurwitz ES, Johnson D, Campbell CC, 1981. Resistance of Plasmodium falciparum malaria to surfadoxine-pyrimethamine (Fansidar®) in a refugee camp in Thailand. Lancet i: 1068-1070.
11. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, Ronn A, Gotzsche PC, 1988. Malaria chemoprophylaxis in travellers to East Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. Br Med J 296: 820-822.
12. Gozal D, Hengy C, Fadat G, 1991. Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance. Antimicrob Agents Chemother 35: 373-376.
13. Raccurt CP, Dumestre-Toulet V, Abraham E, Le Bras M, Brachet-Liermain A, Ripert C, 1991. Failure of falciparum malaria prophylaxis by mefloquine in travelers from West Africa. Am J Trop Med Hyg 45: 319-324.
14. Brasseur P, Kouamouo J, Moyou RS, Druilhe P, 1990. Emergence of mefloquine-resistant malaria in Africa without drug pressure. Lancet 336: 59.
15. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, White NJ, 1991. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 337: 1140-1143
16. Rouvelx B, Bricaire F, Michon C, Franssen G, Le Bras J, Bernard J, Ajana F, Vienne JL, 1989. Mefloquine and an acute brain syndrome. Ann Intern Med 110: 577-578.
17. Stuiver PC, Lightelm RJ, Goud TJ, 1989. Acute psychosis after mefloquine. Lancet ii: 282.
18. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD, 1991. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45: 86-91.
19. Shmuklarsky MJ, Boudreau EF, Pang LW, Smith JI, Schneider I, Fleckenstein L, Abdelrakim MM, Canfield, CJ, Schuster B, 1994. Failure of doxycycline as a causal prophylactic agent against Plasmodium falciparum malaria in healthy nonimmune volunteers. Ann Intern Med 120: 294-299.
20. Nevill CG, Watkins WM, Carter JY, Munsfu CG, 1988. Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria. Br Med J 297: 401-403.
21. Limsomwong N, Pang LW, Singharaj P, 1988. Malaria prophylaxis with proguanil in children living in a malaria-endemic area. Am J Trop Med Hyg 38: 231-236.
22. Carrington HC, Crother AF, Davey DG, Levi AA, Rose FL, 1951. A metabolite of Paludrine with high antimalarial activity. Nature 168: 1080.
23. Watkins WM, Sixsmith DG, Chulay JD, 1984. The activity of proguanil, cycloguanil and p-chlorophenylbiguanide against Plasmodium falciparum in vitro. Ann Trop Med Parasitol 78: 273-278.
24. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM, 1991. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism -a panel study. Br J Clin Pharmacol 31: 689-692.
25. Brosen K, Skjelbo E, Flachs H, 1993. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 36: 105-108.
26. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, Liao C-L, Zhang L-M, 1989. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46: 198-207.
27. Sohn D-R, Kusaka M, Ishizaki T, Shin S-G, Jang I-J, Shin J-G, Chiba K, 1992. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 52: 162-169.
28. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T, 1994. Dapsone N-acetylation, metoprolol α-hydroxylation and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population. A cocktail and extended phenotyping assessment trial. Clin Pharmacol Ther 56: 142-153.
29. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson CR, Branch RA, 1985. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402-408.
30. Wilkinson CR, Guengcrich FP, Branch RA, 1989. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43: 53-76.
31. Alvan G, Bechtel P, Iselius L, Gundert-Remy U, 1990. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537.
32. Kelly JA, Fletcher KA, 1986. High performance liquid chromatographic method for the determination of proguanil and cycloguanil in biological fluids. J Chromatogr 381: 464-471.
33. Edstein MD, 1986. Simultaneous measurement of proguanil and cycloguanil in human plasma by high performance liquid chromatography. J Chromatogr 380: 184-189.
34. Taylor RB, Moody RR, Ochekpe NA, 1987. Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguantde in plasma, whole blood and urine. J Chromatogr 416: 394-399.
35. Taylor RB, Behrens R, Moody RR, Wangboonskul J, 1990. Assay method for the simultaneous determination of proguanil, chloroquine and their major metabolites in biological fluids. J Chromatogr 527: 490-497.
36. Chaulet J-F, Grelaud G, Bellemin-Magninot P, Mounier C, Brazier J-L, 1994. Simultaneous determination of chloroquine, proguanil and their metabolites in human biological fluids by high-performance liquid chromatography. J Pharm Biomed Anal 12: 111-117.
37. Koyama E, Sohn D-R, Shin S-G, Chiba K, Shin J-G, Kim Y-H, Echizen H, Ishizaki T, 1994. Metabolic disposition of imipramine in Oriental subjects: relation to metoprolol α-hydroxylation and S-mephenytoin 4′-hydroxyolation phenotypes. J Pharmacol Exp Ther 271: 860-867.
38. Kupfer A, Preisig R, 1984. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753-759.
39. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK, 1990. Variability in the metabolism of proguanil to the native metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 84: 492-495.
40. Helsby NA, Ward SA, Howells RB, Breckenridge AM, 1990. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol 30: 287-291.
41. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME, 1994. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 37: 413-420.
42. Karwacki JJ, Shanks GD, Limsomwong N, Singharaj P, 1990. Proguanil-sulphonamide for malaria prophylaxis. Trans R Soc Trop Med Hyg 84: 55-57.
43. Pang LW, Limsomwong N, Singharaj P, Canfield CJ, 1989. Malaria prophylaxis with proguanil and sulfisoxazole in children living in a malaria endemic area. Bull World Health Organ 67: 51-58.
44. Shanks GD, Edstein MD, Suriyamongkol V, Timaad S, Webster HK, 1992. Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg 46: 643-648.
45. Edstein MD, Shanks GD, Teja-Isavadharm P, Rieckman KH, Webster HK, 1994. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br J Clin Pharmacol 37: 67-70.